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Post-transcriptional gene silencing is a promising therapy for the monogenic, autosomal dominant, 
Huntington’s disease (HD). However, wild-type huntingtin (HTT) has important cellular functions, 
so the ideal strategy would selectively lower mutant HTT while sparing wild-type. HD patients were 
genotyped for heterozygosity at three SNP sites, before phasing each SNP allele to wild-type or mutant 
HTT. Primary ex vivo myeloid cells were isolated from heterozygous patients and transfected with SNP-
targeted siRNA, using glucan particles taken up by phagocytosis. Highly selective mRNA knockdown 
was achieved when targeting each allele of rs362331 in exon 50 of the HTT transcript; this selectivity 
was also present on protein studies. However, similar selectivity was not observed when targeting 
rs362273 or rs362307. Furthermore, HD myeloid cells are hyper-reactive compared to control. Allele-
selective suppression of either wild-type or mutant HTT produced a significant, equivalent reduction in 
the cytokine response of HD myeloid cells to LPS, suggesting that wild-type HTT has a novel immune 
function. We demonstrate a sequential therapeutic process comprising genotyping and mutant HTT-
linkage of SNPs, followed by personalised allele-selective suppression in a small patient cohort. We 
further show that allele-selectivity in ex vivo patient cells is highly SNP-dependent, with implications for 
clinical trial target selection.
Huntington’s disease (HD) is a fatal, autosomal dominant neurodegenerative disorder caused by a CAG repeat 
expansion in the huntingtin (HTT) gene1. Production of the mutant (m)HTT protein is the primary cause of 
pathology, and numerous studies have demonstrated that lowering cellular levels of mHTT using siRNA or 
antisense oligonucleotides is beneficial in animal models2–4. Most studies have utilised non-selective suppres-
sion of both mHTT and wild-type HTT, whereby the target nucleotide sequence is present on both HTT alleles. 
However, wild-type HTT has important roles in cellular function1, and although preclinical data suggests that 
partial lowering of wild-type HTT is tolerated in the adult brain4–6, intuitively the optimal strategy would selec-
tively lower mHTT while sparing wild-type.
Allele-selective suppression may be achieved by genotyping HD patients to identify heterozygous single 
nucleotide polymorphisms (SNPs) in the HTT gene, before delivering siRNA specific for the SNP allele that is 
mHTT-associated7. Genotyping studies have suggested that 75% of Caucasian HD gene carriers would be treat-
able with five siRNAs targeting three SNPs8, and SNP-targeting strategies have been used successfully in human 
fibroblast and stem cell lines, as well as in  transgenic mouse models of HD9–11. However, allele-selective suppres-
sion of mHTT has not yet been demonstrated in easily accessible primary ex vivo HD patient cells, with samples 
taken from a cohort of patients whose genotype was not known a priori. Carrying out a sequential workflow 
comprising personalised genotyping and mHTT suppression is key to determining the practical relevance of this 
approach, and has relevance to future potential HD clinical trials aimed at lowering mHTT.
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Results
Allele-selective HTT suppression in HD patient cells using siRNA targeted to rs362331. We 
utilised siRNAs designed against the SNPs rs362331 in exon 50 (39.4% heterozygous C/T), rs362273 in exon 57 
(35.2% heterozygous A/G) and rs362307 in the 3′-UTR (48.6% heterozygous C/T) of the HTT transcript. The 
siRNAs targeted to rs362273 and rs362307 have previously demonstrated good selectivity using luciferase assays 
in HeLa cells8. However, the siRNAs designed against rs362331 have not been previously published. As the T allele 
of rs362307 is linked to mHTT  8, testing siRNA targeting the C allele was unnecessary. Diagnostic DNA samples 
were analysed to determine individual SNP genotypes for a cohort of HD patients; we identified fifty-seven indi-
viduals who were heterozygous for rs362331, thirty-eight who were heterozygous for rs362273 and fifty-four who 
were heterozygous for rs362307. Monocyte-derived macrophages were then isolated from repeat peripheral blood 
samples donated by a subset of the heterozygous individuals. Transfection was carried out using glucan-encapsu-
lated siRNA particles (GeRPs), which are taken up by phagocytosis before releasing their siRNA contents into the 
cytoplasm of the target cell. Cultures were harvested 72 h after transfection and mRNA expression was analysed 
by allele-specific qPCR. Previously validated non-selective anti-total HTT siRNA was used as a positive control12.
Targeting rs362331 with anti-U siRNA resulted in 74% on-target U allele suppression, compared to 17% 
off-target C allele suppression (Fig. 1a). Targeting this SNP with anti-C siRNA resulted in 63% on-target sup-
pression, with 30% off-target suppression. Post-hoc testing revealed the discrimination between alleles to be 
significant for each siRNA (p < 0.05). Indeed, in both cases on-target knockdown was equivalent to non-selective 
siRNA, while off-target knockdown was not statistically significant compared to nonsense control.
Unfortunately, comparable selectivity was not achieved when testing siRNAs targeted to either rs362273 or 
rs362307 (Fig. 1b,c). Although post-hoc testing demonstrated statistically significant allelic discrimination fol-
lowing treatment with the rs362273 anti-G siRNA, mean off-target knockdown of this degree is clearly too great 
to consider the particular siRNAs to be truly selective. These data are consistent with the poor discrimination 
previously seen when testing siRNA against rs362307 in cell lines and animal models11,13.
Selective suppression of mHTT protein in HD patient cells using siRNA targeted to 
rs362331. We next validated that total (polyQ-independent) and mHTT (polyQ-expanded) protein levels 
were similarly reduced; analysis was again carried out 72 h after transfection with siRNAs targeted to either allele 
of rs362331. As the siRNAs targeted to rs362273 and rs362307 did not achieve significant mRNA selectivity, 
it was decided not to advance their use to protein studies. To determine which siRNA was targeting mHTT, 
each patient’s SNP alleles were linked to either wild-type or mHTT using the SNP linkage by circularization 
technique12; the T allele of rs362331 was located on the mHTT allele in each subject used for protein analysis. 
As expected, we observed equivalent suppression of total HTT following treatment with each allele-selective 
siRNA, demonstrating that their effects on total HTT levels are independent of mHTT-linkage (Fig. 2a). However, 
we only observed significant suppression of mHTT compared to nonsense control with mHTT-targeted anti-U 
siRNA, with no significant reduction in mHTT following treatment with wild-type targeted anti-C siRNA 
(Fig. 2b). This result shows that the selectivity seen when targeting mRNA at rs362331 also affects the protein 
level.
Allele-selective suppression of wild-type and mHTT reverses the hyper-reactive phenotype of 
human HD myeloid cells. Previous work has shown that HD myeloid cells are hyper-reactive compared to 
control cells in response to stimulation with LPS and IFNγ 14. This phenotype was found to be reversible following 
non-selective HTT suppression with siRNA. To address whether allele-selective suppression has similar effects, 
we stimulated monocyte-derived macrophages with LPS and IFNγ 72 h after treatment with allele-selective 
GeRPs targeting either allele of rs362331. Production of IL-6, IL-8 and TNFα was measured 24 h later. Since we 
observed no significant differences between the mRNA knockdown provided by the anti-U and anti-C siRNAs, 
the samples were grouped for analysis into anti-wild-type and anti-mHTT following SNP linkage to mHTT. 
Interestingly, allele-selective suppression of either wild-type or mHTT produced a significant reduction in the 
levels of each cytokine compared to nonsense control (Fig. 3). No differences in cytokine production were found 
when selectively suppressing mutant compared to wild-type HTT.
Discussion
We demonstrate the first example of a complete sequential workflow comprising SNP genotyping, SNP linkage, 
and personalised allele-selective suppression with phenotypic reversal of an HD-related cellular deficit in het-
erozygous primary ex vivo patient cells. We achieved this through repeated sampling of a small patient cohort, 
using siRNA targeted to rs362331 in exon 50 of the HTT gene. These genotyping techniques would form the 
basis of allele-selective treatment in the clinic, and our study demonstrates their first use in combination, instead 
of individually as part of a technical study8,15. Indeed, blood cells are likely to be used for genotyping in clinical 
trials due to their easy accessibility, and provide a convenient screening tool for novel therapeutics. Although we 
saw reduced suppression of protein relative to mRNA, we consider this is likely due to the longer protein half-life 
allowing more pre-existing species to persist up to 72 h.
These data reinforce previous studies demonstrating that the potency and selectivity of mHTT suppression 
varies considerably depending on the SNP being targeted9,11. While we observed significant allele-selectivity 
using siRNAs targeted to both alleles of rs362331, we did not see similar effects when targeting either rs362273 
or rs362307; this is likely due to additional factors including the nucleotide sequence and tertiary structure of 
the transcript surrounding the base mismatch. rs362307 is a particularly challenging target for allele-selective 
suppression as the surrounding sequence is extremely GC rich, with the SNP comprising a pyrimidine mismatch 
(purine mismatches typically confer greater selectivity)7. Indeed, this SNP has now demonstrated poor selectiv-
ity across multiple research groups and studies11,13. While previous work has shown that adding an additional 
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Figure 1. Characterisation of allele-selective siRNAs targeted to three SNPs in heterozygous human HD 
patient cells. Monocyte-derived macrophages were isolated from SNP-genotyped HD patients and treated with 
GeRPs containing either nonsense, anti-total HTT or allele-selective siRNA targeted to (a) rs362331 in exon 50, 
(b) rs362273 in exon 57 or (c) rs362307 in the 3′-UTR of the HTT transcript. Expression of each SNP allele was 
then measured 72 h later by qPCR. Data show mean expression of each SNP allele ± SEM (n = 3 for rs362331, 
n = 4 for rs362273 and rs362307), statistical analysis carried out using two-way ANOVA with Bonferroni post-
tests. Asterisks above the horizontal line at the top of each graph show significance on ANOVA across the whole 
experiment before post-hoc testing. Asterisks above individual bars represent post-test significance for the 
mRNA expression of that allele compared to the same allele in the nonsense-treated samples. Asterisks above 
horizontal lines between two bars denote allele expression differences within the same treatment on post-hoc 
testing. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. N = individual biological repeats.
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base mismatch in the siRNA sequence can improve selectivity (often at the cost of reduced potency)8, the results 
seen with our anti-rs362307 siRNA suggest that the benefits of this approach may be limited. These data further 
demonstrate the importance of testing potential therapeutics in primary patient cells containing endogenous 
expression of full-length HTT, as these siRNAs achieved promising selectivity during preliminary testing with a 
short construct attached to a luciferase reporter8.
We further utilised allele-selective suppression to investigate the cytokine response of HD myeloid cells. HD 
myeloid cells produce increased levels of proinflammatory cytokines compared to control following stimulation 
with LPS14. This phenotype is due to an exaggerated NFκ B signalling response caused by a direct interaction 
of mHTT with IKK, a key cytoplasmic regulator of NFκ B16. NFκ B signalling has recently been shown to be 
upregulated even in resting HD myeloid cells, and contributes to an abnormal proinflammatory transcriptional 
profile in the absence of any stimulation17. However, very little is known about whether wild-type HTT also 
has a role in innate immune function. If HTT’s effects on cytokine production were limited exclusively to the 
mutant form, it would be expected that selective mHTT-lowering would reduce cytokine production more than 
selective wild-type lowering. However, we saw no significant differences in cytokine production between the 
allele-selective treatment groups. These results suggest that wild-type HTT has an as yet undefined role in nor-
mal immune cell function, and is consistent with previous work showing that cytokine production by control 
myeloid cells is also reduced following HTT-lowering14. Although none of the differences reached statistical sig-
nificance, the mean IL-6 and TNFα levels measured following total HTT-lowering  were less than 50% of those 
Figure 2. Selective suppression of mHTT protein in human HD patient cells using siRNA targeted to 
rs362331. Monocyte-derived macrophages were isolated from HD patients heterozygous for rs362331 with 
linkage of the T allele to mHTT, before treating with GeRPs containing either nonsense, anti-total HTT or 
allele-selective siRNA targeted to each allele of rs362331. Expression of (a) total and (b) mutant HTT protein 
was measured after 72 h using MSD assays, before normalisation to total cellular protein content as measured 
by BCA assays. Data show mean protein levels ± SEM (n = 5), statistical analysis carried out using one-way 
ANOVA with Tukey post-hoc testing. Asterisks above the horizontal line at the top of each graph show 
significance on ANOVA across the whole experiment before post-hoc testing. Asterisks above bars show post-
test significance for each siRNA compared to the nonsense-treated samples. *P < 0.05, **P < 0.01, ***P < 0.001, 
****P < 0.0001. N = individual biological repeats.
www.nature.com/scientificreports/
5Scientific RepoRts | 7:46740 | DOI: 10.1038/srep46740
measured following selective lowering of either the mutant or wild-type allele. This result suggests that total 
cellular HTT load may be an important factor influencing cytokine production, as the sparing of one allele by 
the allele-selective siRNAs will result in less overall knockdown than that achieved by anti-total HTT siRNA. 
However, a full investigation of this hypothesis is beyond the scope of this study.
Figure 3. Allele-selective suppression of wild-type and mHTT reverses the hyper-reactive phenotype of 
human HD myeloid cells. Monocyte-derived macrophages were isolated from SNP-genotyped HD patients 
and treated with GeRPs containing either nonsense, anti-total HTT or allele-selective siRNA targeted to each 
allele of rs362331. Linkage of each SNP allele to either wild-type or mHTT was determined using the SNP 
linkage by circularization protocol. After 72 h the macrophages were stimulated with LPS and IFNγ , before 
the culture supernatants were collected after a further 24 h and analysed using MSD assays. Cytokine values 
were normalised to total protein content as measured by BCA assays. Data show mean cytokine levels ± SEM 
(n = 5 for IL-6 and TNFα , n = 4 for IL-8), statistical analysis carried out using one-way ANOVA with Tukey 
post-hoc testing. Asterisks above the horizontal line at the top of each graph show significance on ANOVA 
across the whole experiment before post-hoc testing. Asterisks above bars show post-test significance for each 
siRNA compared to the nonsense-treated samples. *P < 0.05, **P < 0.01, ***P < 0.001. N = individual biological 
repeats.
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Finally, as rs362307 is the most prevalent SNP in Caucasian HD patients with 48.6% heterozygosity8, it should 
not be assumed that the optimal SNPs will be targetable when estimating what percentage of HD patients may 
benefit from allele-selective therapeutics. As a result, it may be necessary to target less prevalent SNPs to improve 
selectivity, with a subsequent reduction in the treatable proportion of the HD patient population. Non-selective 
therapeutics are therefore likely to be used to treat the majority of adult HD patients, as partial HTT-lowering 
has been shown to be well tolerated in the mature brain4,5. However, the deleterious effects associated with HTT 
knockout in the developing brain6 suggest that an allele-selective strategy may be more useful for treating pre-
symptomatic young adults. We demonstrate that rs362331 may be a promising candidate for this approach.
Methods
Collection and genotyping of human samples. Experiments were performed in accordance with the 
Declaration of Helsinki and approved by the University College London (UCL)/UCL Hospitals Joint Research 
Ethics Committee (REC 03/N008). All subjects provided informed written consent. SNP genotyping was carried 
out by amplifying the SNP with FlashTaq 2X Master Mix, before sequencing by GeneWiz, Inc. (South Plainfield, 
NJ). Primer sequences for amplification were as follows: rs362331 forward: GGGCATTCTGTGACTCGGTA; 
rs362331 reverse: GATAGGAACCCACCGTTCAT; rs362273 forward: AGTGACAAATCCCCAAGACC; 
rs362273 reverse: GAGCTTTTCTCCTGGGTGTG; rs362307 forward: GCTCTGCTCGCTCTCCAG; rs362307 
reverse: GCAGAGACACGCACGTTG. SNP linkage to mHTT was performed using the SNP linkage by circular-
ization technique, using previously published methodology15. Details of the subject cohort used for each experi-
ment are contained in Supplementary Table S1.
HTT suppression. GeRPs were synthesised and loaded with siRNA according to previously published method-
ology18. siRNA guide sequences were as follows: nonsense: 5′ -pUUUCGAAGUACUCAGCGUGAG-3′ ; anti-total 
HTT: 5′-pUUCAUCAGCUUUUCCAGGGUC-3′ ; rs362331 anti-C: 5′ -pUUACACAGUGGAUGAGGGAGC-3′ ; 
rs362331 anti-U: 5′ -pGUACACAGUAGAUGAGGGAGC-3′ ; rs362273 anti-A: 5′ -pUUUGAUUUGU 
AGCAGCAGCUU-3′ ; rs362273 anti-G: 5′ -pUUUGCUCUGCAGCAGCAGCUU-3′ ; rs362307 anti-U: 5′ -pCACAC 
GGGCACAGACUUCCAA-3′ . The siRNA Sequence Probability-of-Off-Targeting Reduction (siSPOTR) algo-
rithm (https://sispotr.icts.uiowa.edu/sispotr/index.html) was used to identify additional transcripts with 
the potential for off-target suppression. Genes with an individual transcript Probability of Off-Target Score 
(tPOTS) ≥ 0.2 were then analysed using the GO annotation enrichment analysis tool (http://www.geneontology.
org/) to identify overlapping biological processes. A complete list of siSPOTR results and GO pathways for the 
rs362331 siRNAs is contained in Supplementary Data S1.
To test the siRNAs, monocytes were isolated from peripheral blood samples by density centrifugation and 
magnetic cell sorting, before differentiation into macrophages as previously described14. Transfection was carried 
out on day three of the differentiation protocol by changing to fresh media containing GeRPs at a 10:1 particle 
to cell ratio. GeRPs were removed after 24 h by complete media change; this protocol achieves 90% transfection 
efficiency. Huntingtin mRNA and protein levels were then measured after a further 48 h in culture.
Allele-specific qPCR. Custom TaqMan® probes were designed for each SNP allele, before TaqMan® 
Gene Expression Master Mix was used to analyse allele-specific HTT expression. Primers used for 
allele-specific qPCR were as follows: rs362331 forward: CTGGAGCGTGGTCTCCTCCACA; rs362331 reverse: 
GTGTGTTTGGATCTACTTCCTCC; rs362273 forward: CTACTACAGGTGCCCTCATCAG; rs362273 
reverse: GTGACGAAGGTGCAGGGGCGTC; rs362307 forward: ATGGTGGGAGAGACTGTGAGGC; 
rs362307 reverse: ATGGCAGAGACACGCACGTTGC. Probes used for allele-specific qPCR were as follows: 
rs362331 C: 6FAM-TCCCTCATCCACTGTGTGC-MGBNFQ; rs362331 T: VIC-TCCCTCATCTACTGT 
GTGC-MGBNFQ; rs362273 A: 6FAM-GCTGCTGCTACAGATCAAC-MGBNFQ; rs362273 G: VIC- 
GCTGCTGCTGCAGATCAAC-MGBNFQ; rs362307 C: 6FAM-TGGAAGTCTGCGCCCTTGTG-MGBNFQ; 
rs362307 U: VIC-TGGAAGTCTGTGCCCTTGTG-MGBNFQ. Primers and probes were used at final concentra-
tions of 500 nM and 150 nM respectively. Thermal cycling conditions were as follows: 50 °C for 2 min and 95 °C 
for 10 min followed by forty cycles of 95 °C for 15 s and either 65 °C (for rs362331 and rs362273) or 67.5 °C (for 
rs362307) for 1 min. GAPDH and ACTB were used as reference genes.
HTT protein quantification assays. Total (polyQ-independent) and mHTT (polyQ-dependent) protein 
levels were measured by Meso Scale Discovery (MSD) assays using a protocol adapted from published methods19. 
2B7 and biotinylated-4C9 were used as the antibody pair for detection of total HTT20, while 2B7 and biotinylated 
MW1 were used as the antibody pair for detection of mHTT21. Readings were normalised to total protein content 
of the sample as measured by BCA assays.
MSD cytokine assays. Monocyte-derived macrophages were stimulated by changing to fresh media con-
taining 2 μ g/ml LPS and 10 ng/ml IFNγ 72 h after GeRP treatment. After a further 24 h the supernatants were ana-
lysed using the V-PLEX Human Proinflammatory Panel II (4-Plex) Kit. IL-1β was not included in the analysis as 
previous work has shown that its production is not upregulated in HD myeloid cells14. Readings were normalised 
to total protein content of the sample as measured by BCA assays.
Statistical analysis. Statistical analysis was carried out using GraphPad Prism 6 (GraphPad). Analysis of 
mRNA knockdown was performed using two-way ANOVAs with Bonferroni post-hoc multiple comparison test-
ing. Protein knockdown and cytokine profiling experiments were analysed using one-way ANOVAs with Tukey 
post-hoc multiple comparison testing. All error bars represent standard error of the mean.
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